In Chronic Myeloid Leukemia (CML) Patients with Complete Cytogenetic Response to Imatinib, BCR-ABL Kinase Domain Mutations Are Relatively Rare and Not Consistently Associated with Subsequent Relapse.
Daniel W. Sherbenou(University of Colorado Anschutz Medical Campus), Michael W. Deininger(Versiti Blood Center of Wisconsin), Laura McGreevey(Novartis (Switzerland)), Brian Druker(Oregon Health & Science University), Richard D. Press(Oregon Health & Science University), Michael C. Heinrich(VA Portland Health Care System), Adil Humayun(Oregon Health & Science University), Matthew J. Wong, Rui Yang(Tianjin University of Science and Technology)
Cited by 6
Related Papers
Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
|New England Journal of Medicine|2002|2k
Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group
|Journal of Clinical Oncology|2008|655
Imatinib for Melanomas Harboring Mutationally Activated or Amplified <i>KIT</i> Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin
|Journal of Clinical Oncology|2013|594
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
|New England Journal of Medicine|2019|464